An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

Publication: 2021- : Basel, Switzerland : MDPI
Original Publication: Toronto : Multimed, c1994-

Breast Neoplasms*/drug therapy ; Premenopause* ; Gonadotropin-Releasing Hormone*/agonists ; Gonadotropin-Releasing Hormone*/therapeutic use ; Goserelin*/therapeutic use; Humans ; Female ; Antineoplastic Agents, Hormonal/therapeutic use ; Survivorship

Managing breast cancer in premenopausal women poses unique challenges due to its considerable effect on both morbidity and mortality. Goserelin, a gonadotropin-releasing hormone agonist, has emerged among the various modalities as a preferred option for ovarian function suppression, owing to its efficacy in reducing ovarian estrogen production in premenopausal women with hormone receptor-positive breast cancer. Recent studies have affirmed the efficacy and safety of long-acting (LA) goserelin 10.8 mg every 12 weeks, offering comparable outcomes to monthly injections. This flexibility enables personalized treatment approaches, potentially enhancing patient satisfaction. Off-label utilization of goserelin LA surged during the coronavirus disease pandemic, prompting initiatives to broaden its use for breast cancer treatment. Switching to goserelin LA can streamline treatment, boost adherence, and optimize resource utilization. With the recent approval of goserelin 10.8 mg LA by Health Canada on 6 May 2024, for use in breast cancer, Canada is the latest to join over 60 countries worldwide to expand the accepted indications for goserelin LA and ensure its availability to potentially enhance healthcare delivery, patient care, and breast cancer outcomes. Goserelin LA offers premenopausal patients a means to more effectively manage the constraints imposed by breast cancer treatment and its impact on survivorship.

Clin Breast Cancer. 2018 Oct;18(5):e939-e942. (PMID: 29747931)
Breast Cancer Res Treat. 2011 Apr;126(2):443-51. (PMID: 21221770)
N Engl J Med. 2015 Jan 29;372(5):436-46. (PMID: 25495490)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Mol Cell Endocrinol. 2021 Apr 5;525:111181. (PMID: 33529690)
N Engl J Med. 2016 Aug 25;375(8):717-29. (PMID: 27557300)
J Clin Oncol. 2019 Feb 10;37(5):423-438. (PMID: 30452337)
Maturitas. 2010 Feb;65(2):161-6. (PMID: 19733988)
J Natl Compr Canc Netw. 2019 May 1;17(5.5):552-555. (PMID: 31117035)
Int J Mol Sci. 2023 Dec 29;25(1):. (PMID: 38203649)
Anticancer Res. 2002 Jul-Aug;22(4):2325-32. (PMID: 12174922)
Mol Clin Oncol. 2019 Nov;11(5):517-522. (PMID: 31620283)
Ann Oncol. 2019 Aug 1;30(8):1194-1220. (PMID: 31161190)
Breast J. 2016 Nov;22(6):667-672. (PMID: 27542172)
Breast Cancer. 2017 Jan;24(1):161-170. (PMID: 27017207)
J Clin Oncol. 2016 May 10;34(14):1689-701. (PMID: 26884586)
NPJ Breast Cancer. 2024 Jan 19;10(1):8. (PMID: 38242892)
Front Oncol. 2021 Sep 14;11:700722. (PMID: 34595110)
J Gynecol Obstet Hum Reprod. 2018 Jun;47(6):261-264. (PMID: 29510273)
J Clin Oncol. 2020 Apr 20;38(12):1293-1303. (PMID: 31618131)
J Clin Oncol. 2017 Sep 20;35(27):3113-3122. (PMID: 28654365)
Breast Cancer Res Treat. 2024 Aug;206(3):543-550. (PMID: 38709374)
Reprod Health. 2022 Jan 31;19(1):29. (PMID: 35101087)
J Clin Oncol. 2007 Jun 20;25(18):2509-15. (PMID: 17577027)
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13051. (PMID: 31033073)
Lancet Oncol. 2021 Apr;22(4):476-488. (PMID: 33721561)
N Engl J Med. 2021 Dec 16;385(25):2336-2347. (PMID: 34914339)
Breast Cancer. 2021 May;28(3):684-697. (PMID: 33638810)
Breast Cancer. 2016 Sep;23(5):771-9. (PMID: 26350351)
J Breast Cancer. 2020 Oct 26;23(5):553-559. (PMID: 33154830)
Breast Cancer. 2016 May;23(3):499-509. (PMID: 25655898)
BMC Cancer. 2009 Apr 21;9:117. (PMID: 19383123)
Curr Oncol. 2020 Oct;27(5):e516-e523. (PMID: 33173392)
Breast Cancer Res Treat. 2021 Nov;190(2):183-188. (PMID: 34498153)
Curr Drug Targets. 2020;21(9):910-921. (PMID: 32077823)
Ann Clin Biochem. 2018 Jan;55(1):18-33. (PMID: 29027807)
J Clin Oncol. 2016 May 10;34(14):1584-93. (PMID: 26729437)
Curr Opin Oncol. 2019 Jan;31(1):43-51. (PMID: 30299291)
BMC Public Health. 2014;14 Suppl 3:S8. (PMID: 25437351)
Patient Prefer Adherence. 2023 Oct 31;17:2679-2706. (PMID: 37927344)
Oncologist. 2021 Jun;26(6):e936-e942. (PMID: 33594769)
Breast Care (Basel). 2015 Apr;10(2):95-100. (PMID: 26195937)
J Clin Oncol. 2016 May 10;34(14):1601-10. (PMID: 27022111)
Br J Surg. 2019 Feb;106(3):236-244. (PMID: 30229870)
J Clin Oncol. 2018 Jul 1;36(19):1981-1990. (PMID: 29718793)
Cancer Treat Rev. 2017 Apr;55:26-35. (PMID: 28288389)
Adv Exp Med Biol. 2020;1252:181-187. (PMID: 32816280)
PLoS One. 2022 Feb 25;17(2):e0264637. (PMID: 35213669)
Front Oncol. 2019 Oct 01;9:943. (PMID: 31632902)
N Engl J Med. 2023 May 4;388(18):1645-1656. (PMID: 37133584)
N Engl J Med. 2018 Jul 12;379(2):122-137. (PMID: 29863451)
Breast. 2022 Dec;66:204-207. (PMID: 36327626)
J Natl Cancer Inst. 2018 Dec 1;110(12):1311-1327. (PMID: 30403799)
Lancet Oncol. 2022 Mar;23(3):382-392. (PMID: 35123662)

Keywords: GnRH; LHRH agonist; breast cancer adjuvant therapy; goserelin; hormone receptor-positive breast cancer; long-acting; ovarian function suppression; premenopausal; survivorship

33515-09-2 (Gonadotropin-Releasing Hormone)
0F65R8P09N (Goserelin)
0 (Antineoplastic Agents, Hormonal)

Date Created: 20240828 Date Completed: 20240828 Latest Revision: 20240830

20240830

PMC11352532

10.3390/curroncol31080314

39195297